<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/455949</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Molecular Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Umbelliprenin isolated from <italic>Ferula sinkiangensis</italic> inhibits tumor growth and migration through the disturbance of Wnt signaling pathway in gastric cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Lijing</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="aff" rid="a2">b</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sun</surname><given-names>Xiaobo</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Si</surname><given-names>Jianyong</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Guangzhi</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Cao</surname><given-names>Li</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<aff id="a1"><label>a</label><institution>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences &#x0026; Peking Union Medical College</institution>, Beijing, <country>China</country></aff>
<aff id="a2"><label>b</label><institution>Institute of Food Science and Technology, Chinese Academy of Agricultural Sciences (CAAS)</institution>, Beijing, <country>China</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Corresponding author Prof. Li Cao, E-mail address: <email>lcao@implad.ac.cn</email>, Tel.: &#x002B;86-010-57833222;, Fax: &#x002B;86-010-57833222, Postal address: 151# Malianwa North Road, Haidian District, Beijing 100193, China.</corresp>
</author-notes>
<pub-date pub-type="epub"><year>2018</year></pub-date>
<elocation-id>455949</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>29</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="455949.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract><title>Abstract</title>
<p><bold>The traditional</bold> herb medicine <italic>Ferula sinkiangensis</italic> K. M. Shen <bold>(<italic>F.</italic> sinkiangensis)</bold> has been used to treat stomach disorders in Xinjiang District for centuries. Umbelliprenin is the effective component isolated from <italic>F. sinkiangensis</italic> which is particularly found in plants of the family Ferula. We previously reported the promising effects of Umbelliprenin against gastric cancer cells, but its <bold>anti-migration</bold> effect <bold>remained</bold> unknown. Here we investigated the <bold>anti-migration</bold> effect and mechanism of Umbelliprenin in human gastric cancer cells. In SRB assay, Umbelliprenin showed cytotoxic activities in <bold>the</bold> gastric cancer cell lines AGS and BGC-823 in a dose-and-time-dependent manner, while it showed <bold>lower</bold> cytotoxic activity in <bold>the</bold> normal gastric epithelium cell <bold>line</bold> GES-1. During transwell, scratch and colony assays, the <bold>migration</bold> of tumor cells was inhibited <bold>by</bold> Umbelliprenin treatment. <bold>The expression levels of the Wnt-associated signaling pathway proteins were analyzed with western blots, and the results showed that</bold> Umbelliprenin decreased the expression levels of <bold>proteins of the Wnt signalling pathway, such as</bold> Wnt-2, &#x03B2;-catenin, GSK-3&#x03B2;, p-GSK-3&#x03B2;, Survivin and c-myc. The translocation of &#x03B2;-catenin to the nucleus was also inhibited <bold>by</bold> Umbelliprenin treatment. In TCF reporter assay, <bold>the transcriptional activity of T-cell factor/lymphoid enhancer factor (TCF/LEF) was</bold> decreased after Umbelliprenin treatment. <bold>The</bold> <italic>in vivo</italic> results suggested that Umbelliprenin <bold>induced little to no</bold> harm in <bold>the</bold> lung, heart and kidney. Overall, these data provided evidence that Umbelliprenin may inhibit the growth, invasion and <bold>migration</bold> of gastric cancer cells <bold>by disturbing the</bold> Wnt signaling pathway.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Umbelliprenin</kwd>
<kwd>Gastric Cancer</kwd>
<kwd>Wnt signaling</kwd>
<kwd>Metastasis</kwd>
<kwd><italic>Ferula sinkiangensis</italic> K. M. Shen</kwd>
</kwd-group>
<counts>
<page-count count="32"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1"><label>1.</label><title>Introduction</title>
<p>Gastric cancer is the fourth most common cancer worldwide and <bold>is one of</bold> the most prevalent <bold>cancers among</bold> men in China [<xref ref-type="bibr" rid="c1">Kim et al., 2015</xref>; <xref ref-type="bibr" rid="c2">Zheng et al., 2016</xref>], which may be <bold>related to their preference for</bold> pickled food and red meat [<xref ref-type="bibr" rid="c3">Zeng et al., 2015</xref>]. The clinical outcome of gastrointestinal cancer surgery is limited <bold>because of the</bold> high rates of postoperative complications<bold>, such</bold> as <bold>the</bold> systemic inflammatory response [<xref ref-type="bibr" rid="c4">Climent et al., 2015</xref>], which may increase tumor recurrence after surgery [<xref ref-type="bibr" rid="c5">Bohle et al., 2010</xref>]. Therefore, <bold>studies have focused</bold> on raising the overall survival rate for gastric cancer [<xref ref-type="bibr" rid="c6">Cho et al., 2016</xref>]. However, only trastuzumab and ramucirumab <bold>have been</bold> approved for the treatment of advanced gastric cancer as targeted monoclonal antibodies [<xref ref-type="bibr" rid="c7">Roviello et al., 2016</xref>], suggesting that less toxic and more effective therapeutic options are necessary.</p>
<p>Metastasis is the main cause of death in cancer patients [<xref ref-type="bibr" rid="c8">Tang et al., 2014</xref>]. The invasion of cancer cells is affected and modulated by many biological molecules and signaling pathways. Growing <bold>evidence indicates that there are abnormalities in the Wnt pathway</bold> in human gastric cancer [<xref ref-type="bibr" rid="c9">Chiurillo, 2015</xref>]. In the absence of Wnt signals, &#x03B2;-catenin in the cytosol is continuously degraded. On the contrary, in the presence of Wnt signals, the level of &#x03B2;-catenin increases, <bold>and then,</bold> &#x03B2;-catenin accumulates in the cytosol and subsequently translocates to the nucleus <bold>and</bold>, binds to the T-cell factor (TCF)/lymphoid enhancer factor (LEF). <bold>These</bold> transcription factors regulate the expression of specific downstream target genes such as c-myc and Survivin, which are involved in oncogenesis [<xref ref-type="bibr" rid="c10">Chen et al., 2001</xref>; <xref ref-type="bibr" rid="c11">Dong et al., 2015</xref>]. Therefore, the <bold>components of the Wnt signalling pathway could be good molecular targets</bold> for gastric cancer therapy.</p>
<p>Natural products have been used as traditional medicines for gastric cancer therapy [<xref ref-type="bibr" rid="c12">Yang et al., 2013</xref>]. <italic>Ferula sinkiangensis</italic> K. M. Shen is a traditional folk medicine, which <bold>has</bold> been used for <bold>treating stomach disorders</bold> in Xinjiang District since <bold>the</bold> Tang Dynasty. Umbelliprenin is an effective component <bold>of</bold> <italic>F. sinkiangensis</italic> and exhibits anti-cancer effects in many cancer cells lines [<xref ref-type="bibr" rid="c13">Ziai et al., 2012</xref>; <xref ref-type="bibr" rid="c14">Mousavi et al., 2015</xref>]. Our previous studies have first explored the growth inhibition effect of Umbelliprenin in gastric cancer cells<bold>: this compound</bold> could induce apoptosis and cell cycle arrest [<xref ref-type="bibr" rid="c15">Zhang et al., 2015</xref>]. In the present report, we reported that Umbelliprenin <bold>can inhibit tumor</bold> growth and <bold>migration</bold>, and <bold>that</bold> the underlying anticancer mechanism of Umbelliprenin is associated with <bold>the</bold> Wnt signal pathway.</p>
</sec>
<sec id="s2"><label>2.</label><title>Material and methods</title>
<sec id="s2a"><label>2.1</label><title>Reagents and antibodies</title>
<p>Dulbecco&#x2019;s Modified Eagle&#x2019;s Medium (DMEM), Ham&#x2019;s F12 medium, trypsin, penicillin, streptomycin <bold>and</bold> fetal bovine serum (FBS) were purchased from Gibco (CA, USA). <bold>Sulforhodamine B (SRB)</bold> and <bold>Dimethyl Sulphoxide (DMSO)</bold> were purchased from Sigma-Aldrich (MO, USA). Transwell systems were purchased from Corning (NY, USA). Matrigel basement membrane matrix was bought from BD Biosciences (NJ, USA). M50 Super 8x TOPFlash (12457), M51 Super 8x FOPFlash (TOPFlash mutant) (12457) and pRL-SV40P (27163) were obtain from Addgene. Lipofectamine 2000 was <bold>bought</bold> from Thermo (MA, USA). The dual luciferase reporter assay kit was obtained from KeyGEN Biotech (Jiangsu, China). The nuclear and cytoplasmic protein extraction kit was purchased from Beyotime Biotechnology (Jiangsu, China). Antibodies against Wnt-2, GSK-3&#x03B2;, c-myc, &#x03B2;-catenin, p-GSK-3&#x03B2;, Survivin, Lamin B and &#x03B2;-actin were purchased from Cell Signaling Technology (MA, USA). The cECL Western Blot Kit was obtained from CoWin Biotech (Beijing, China). All the chemical reagents were of the highest grade.</p>
</sec>
<sec id="s2b"><label>2.2</label><title>Cell culture and compounds</title>
<p><bold>The</bold> human gastric carcinoma cell line AGS was cultured in Ham&#x2019;s F12 medium containing 10&#x0025; FBS, 100 U/mL penicillin, and 100 &#x03BC;g/mL streptomycin at 37&#x00B0;C with 5&#x0025; CO2. The human normal gastric epithelial cell line GES-1 <bold>and</bold> human gastric cancer cell line BGC-823 were cultured in DMEM supplemented with 10&#x0025; FBS, 100 U/mL penicillin and 100 &#x03BC;g/mL streptomycin under the same conditions. Cells were passaged at least three times before being used in experiments. Umbelliprenin was obtained from the seeds of <italic>F. sinkiangensis</italic> as previously described [<xref ref-type="bibr" rid="c15">Zhang et al., 2015</xref>]. Umbelliprenin was dissolved as stock solutions in dimethyl sulfoxide <bold>that were</bold> diluted with medium prior to use so <bold>that</bold> the final concentration of DMSO was less than 0.1&#x0025; (v/v).</p>
</sec>
<sec id="s2c"><label>2.3</label><title>Animals</title>
<p>Six-week-old male BALB/c nude mice were obtained from <bold>the</bold> Vital River Laboratories (Beijing, China) and maintained <bold>in</bold> a 12 h light/dark cycle environment (25 &#x00B1; 2&#x00B0;C) where they <bold>received</bold> and food ad libitum. The protocol for <bold>the</bold> animal <bold>experiments</bold> was approved by the Animal Ethics Committee at the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences.</p>
</sec>
<sec id="s2d"><label>2.4</label><title>Cell viability assay</title>
<p><bold>The</bold> Sulforhodamine B (SRB) assay was used to determine cell viability. Cells were seeded in 96-well plates in triplicate and cultured for 24 h at 37&#x00B0;C. Then, the cells were treated with Umbelliprenin in various concentrations (<bold>0</bold>, 3.125, 6.25, 12.5, 25, 50 &#x03BC;M). After <bold>the</bold> 24 h treatment, 50 &#x03BC;L <bold>of</bold> cold TCA was added to fix <bold>the</bold> cells for 1 h at 4&#x00B0;C. The plates were washed with water and air-dried. <bold>One-hundred microlitres</bold> of 0.4&#x0025; (w/v) SRB was added and <bold>cells were</bold> stained for 15 min. After washing 4 times with acetic acid, 100 &#x03BC;L <bold>of</bold> Tris-base was added for 10 min, <bold>while shaking</bold>. The absorbance was measured at 540 nm using a Microplate Reader (Bio Tek, USA). &#x0025; Cytotoxicity= (Control &#x2013; Experimental) / Control&#x002A; 100&#x0025;.</p>
</sec>
<sec id="s2e"><label>2.5</label><title>Colony Formation Assay</title>
<p><bold>The</bold> colony formation <bold>assay</bold> was used to evaluate the anchorage-independent growth of gastric cancer cells. Cells were seeded in 6-well plates and treated with Umbelliprenin (0, 6, 12, 24 &#x03BC;M for AGS <bold>cells</bold> and 0, 12.5, 25, 50 &#x03BC;M for BGC-823 <bold>cells</bold>) for 10 days. The tumor colonies were observed counted <bold>using a</bold> microscope. Then, the colonies were stained with crystal violet (<bold>1 mg/mL</bold>), and colonies larger than 200 &#x03BC;m were counted.</p>
</sec>
<sec id="s2f"><label>2.6</label><title>Wound healing Assay</title>
<p>Cell motility was detected using <bold>the</bold> wound healing assay. Cells were cultured in <bold>a</bold> 24-well plate to nearly 90&#x0025; confluence. The monolayers were then carefully scratched using a sterile 200-&#x03BC;L pipette tip with a constant width. The cells were washed with PBS and treated with Umbelliprenin (IC<sub>50</sub> values <bold>were used</bold> in both AGS and BGC-823 <bold>cells</bold>). The cells were photographed at 0, 24, 36 and 48 h after treatment to observe the distances <bold>that the cells had migrated</bold>. The cell motility was calculated as <bold>follows</bold>: Cell motility = (distance at 0 h - distance at 24, 36 or 48 h) / distance at 0 h&#x002A; 100&#x0025;.</p>
</sec>
<sec id="s2g"><label>2.7</label><title>Transwell-migration / invasion assays</title>
<p>Cell migration was analyzed in a 24-well transwell plate with 8-&#x03BC;m pore size polyvinylidene filter membrane. Cells were seeded into the upper chamber (1&#x00D7;10<sup>5</sup>) in serum-free Ham&#x2019;s F12 <bold>medium</bold> and treated with Umbelliprenin (0, 6, 12, 24 &#x03BC;M for AGS <bold>cells</bold> and 0, 12.5, 25, 50 &#x03BC;M for BGC-823 <bold>cells</bold>). Ham&#x2019;s F12 <bold>medium</bold> with 10&#x0025; serum was added to the lower chamber. After incubation for 24 h, <bold>the</bold> cells on the upper side of the filter were removed with cotton swabs, <bold>and</bold> the <bold>filters</bold> were fixed with 4&#x0025; formaldehyde for 10 min at room temperature, <bold>and</bold> stained with crystal violet for 15 min, the number of cells in five random fields of each triplicate filter <bold>was counted</bold> under the light microscope. The cell invasion assay was conducted under similar procedure, except that 80 &#x03BC;L of Matrigel was used to coat <bold>the</bold> upper chamber for 12 h before the cells were seeded.</p>
</sec>
<sec id="s2h"><label>2.8</label><title>&#x03B2;-Catenin / TCF Transcription Reporter Assay</title>
<p><bold>The</bold> TCF-reporter plasmids (TOPFLASH and the negative control FOPFLASH) and Renilla luciferase (pRL-SV40P) plasmid were obtained from Addgene. Cells were seeded in 6-well plates and the reporter plasmids <bold>containing</bold> TCF binding sites (TOPFLASH, 500 ng/well) or mutant, inactive TCF binding sites (FOPFLASH, 500 ng/well) <bold>were</bold> transiently transfected into <bold>the</bold> cells for 6 hours using Lipofectamine 2000. The cells were co-transfected with <bold>the</bold> Renilla luciferase (pRL-SV40P, 5 ng/well) plasmid to normalize <bold>the</bold> transfection efficiency <bold>with</bold> the internal control. Then, the medium was renewed and different concentrations of Umbelliprenin were added. After <bold>the</bold> 24 h treatment, TCF-mediated gene transcription was expressed by the ratio of TOPFLASH: FOPFLASH luciferase activity, and each <bold>value</bold> was normalized to the Renilla luciferase activity.</p>
</sec>
<sec id="s2i"><label>2.9</label><title>Protein isolation and western blot</title>
<p>Fractionated nuclear and cytosolic proteins were obtained according to the manufacturer&#x2019;s instructions. Briefly, cells were treated with Umbelliprenin (0, 6, 12, 24 &#x03BC;M for AGS <bold>cells</bold> and 0, 12.5, 25, 50 &#x03BC;M for BGC-823 <bold>cells</bold>) for 24 h, harvested and washed twice with ice-cold PBS. 500 &#x03BC;<bold>L of</bold> cytoplasmic extract agent A and B were added and <bold>the suspension was</bold> centrifuged at 12,000 rpm for 5 min. The supernatant <bold>contained</bold> cytosolic <bold>proteins</bold>. The nuclear residue was mixed with 200 <bold>&#x03BC;L</bold> of <bold>the</bold> nuclear extract agent. The mixture was vortexed for 30 min and then centrifuged at 14,000 rpm for 10 min at 4&#x00B0;C. The supernatant <bold>contained</bold> nuclear <bold>proteins</bold>.</p>
<p>To obtain whole-cell lysates, cells were lysed in lysis buffer after <bold>treatment</bold> with Umbelliprenin (0, 6, 12, 24 &#x03BC;M for AGS <bold>cells</bold> and 0, 12.5, 25, 50 &#x03BC;M for BGC-823 <bold>cells</bold>) for 24 h and <bold>the</bold> protein concentrations were determined by the BCA method. Protein samples were separated by SDS-PAGE and transferred onto PVDF membranes. After blocking for 1 h in <bold>the</bold> 5&#x0025; non-fat milk solution, the membranes were incubated with <bold>the</bold> primary antibody overnight at 4&#x00B0;C. Then the primary antibody was washed with TBST <bold>for</bold> 3 times and incubated with secondary antibody for 1 h at room temperature. Protein bands were detected using ECL and the levels of &#x03B2;-actin were used to ensure equal loading of proteins.</p>
</sec>
<sec id="s2j"><label>2.10</label><title>Immunofluorescence staining to detect the nuclear translocation of &#x03B2;-catenin</title>
<p>Cells were cultured in plates and treated with Umbelliprenin (0, 6, 12, 24 &#x03BC;M for AGS <bold>cells</bold> and 0, 12.5, 25, 50 &#x03BC;M for BGC-823 <bold>cells</bold>) for 24 h. The treated cells were fixed with 4&#x0025; paraformaldehyde for 10 min and washed <bold>twice with PBS</bold>. These cells were blocked with 5&#x0025; bovine serum albumin in PBS for 60 min, and then incubated with <bold>the</bold> primary antibody (diluted 1:200 in PBS containing 3&#x0025; BSA) overnight at 4&#x00B0;C. After washing twice with PBS, the cells were co-incubated with <bold>the</bold> IgG PE-conjugated secondary antibody (diluted 1:400 in PBS containing 3&#x0025; BSA) and DAPI for 1 h at room temperature. The cells were examined with <bold>the</bold> Image Xpress system (Molecular Devices, USA).</p>
</sec>
<sec id="s2k"><label>2.11</label><title>Safety of Umbelliprenin in tumor xenograft models</title>
<p>Animal <bold>experiments were</bold> conducted according to <bold>the</bold> previous description [<xref ref-type="bibr" rid="c15">Zhang et al., 2015</xref>]. Briefly, mice were inoculated subcutaneously with <bold>the</bold> human gastric cancer cells BGC-823 (1.0 &#x00D7; 10<sup>6</sup>) on the right flank. The mice were randomized to six groups and <bold>their conditions were observed</bold> every day. <bold>Umbelliprenin were diluted in 200 &#x03BC;L 0.9&#x0025; NaCl solution and administered to each mouse at a dose of 10 mg/kg or 20 mg/kg twice daily for 12 days.</bold> Mice were then euthanized and <bold>the</bold> lungs, livers, hearts and kidneys were fixed and preserved in formalin for hematoxylin-eosin staining.</p>
</sec>
<sec id="s2l"><label>2.12</label><title>Statistical analysis</title>
<p>All data were analyzed by <bold>the</bold> IBM SPSS statistics 19 <bold>software</bold>. All tests were conducted at least three times. Statistical significance was defined as &#x002A;p &#x003C; 0.05 and &#x002A;&#x002A;p &#x003C; 0.01. The results were expressed as mean &#x00B1; SD which represent three independent tests.</p>
</sec>
</sec>
<sec id="s3"><label>3.</label><title>Results</title>
<sec id="s3a"><label>3.1</label><title>Umbelliprenin reduced the viability in AGS and BGC-823 human gastric cancer cells, but not in GES-1 cells</title>
<p>The chemical structure of Umbelliprenin isolated from the seeds of <italic>F. sinkiangensis</italic> <bold>is shown</bold> in <bold><xref ref-type="fig" rid="fig1">Figure 1A</xref></bold>. <bold>Because</bold> Umbelliprenin <bold>appeared to be</bold> most effective in gastric cancer <bold>cells</bold> among other common cancer cells, we studied <bold>its</bold> anti-proliferative effects <bold>in the</bold> two human gastric cancer cell lines: AGS <bold>and</bold> BGC-823 <bold>as well as in the</bold> human gastric epithelial cell line GES-1. The IC<sub>50</sub> values for the three cancer cell lines varied. The results showed that Umbelliprenin <bold>inhibited</bold> the growth in both <bold>the</bold> AGS and BGC-823 gastric cancer cell lines with an IC<sub>50</sub> of 11.74 &#x03BC;M and 24.62 &#x03BC;M, <bold>respectively,</bold> the IC<sub>50</sub> for AGS was lower <bold>than that for the BGC-823 cells</bold> (<bold><xref ref-type="fig" rid="fig1">Figure 1C</xref></bold> and <bold><xref ref-type="fig" rid="fig1">Figure 1D</xref></bold>). In addition, Umbelliprenin was less cytotoxic <bold>in</bold> GES-1 cells (IC<sub>50</sub>: 97.55 &#x03BC;M) compared with AGS and BGC-823 cells (<bold><xref ref-type="table" rid="tbl1">Table 1</xref></bold>). Based on <bold>the</bold> IC<sub>50</sub> values, we chose 12 &#x03BC;M <bold>and</bold> 24 &#x03BC;M Umbelliprenin<bold>, as well as their multiples or fractions, as the concentrations for treating</bold> AGS and BGC-823 cells, <bold>respectively</bold>. Furthermore, as the colony formation ability is closely related to tumorigenesis <italic>in vivo</italic>, we detected the impact of Umbelliprenin on the growth of gastric cancer cells. The results showed that Umbelliprenin <bold>significantly</bold> inhibited the colony forming ability of AGS <bold>cells</bold> in a dose-dependent manner, while <bold>it was</bold> less effective in BGC-823 cells (<bold><xref ref-type="fig" rid="fig1">Figure 1B</xref></bold>). Together, these data indicate that Umbelliprenin may decrease the proliferation and tumor forming ability <bold>in AGS and BGC-823 gastric cancer cells</bold>.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure"><label>Figure 1:</label><caption><title>Chemical structure and inhibition effects on cell viability of Umbelliprenin.</title><p><bold>A.</bold> Chemical <bold>structure</bold> of Umbelliprenin isolated from the <bold>seeds</bold> of <italic>Ferula sinkiangensis</italic>. <bold>B.</bold> Colony formation assay. AGS or BGC-823 cells were <bold>grown</bold> for 10 days after incubation with different concentrations of Umbelliprenin. <bold>C.</bold> The effects of Umbelliprenin on the <bold>viability of AGS human gastric cancer cells</bold>. <bold>D.</bold> The effects of Umbelliprenin on the viabilities of human gastric cancer cells BGC-823. AGS and BGC-823 <bold>cells</bold> were exposed to various concentrations of Umbelliprenin (0, 3.125, 6.25, 12.5, 25, 50 &#x03BC;M) for 24 h, 48 h or 72 h, followed by the Sulforhodamine B (SRB) assay. The data represent the mean value of three independent experiments and are expressed as <bold>the mean</bold> &#x00B1; SD. &#x002A;&#x002A;p &#x003C; 0.01, &#x002A;p &#x003C; 0.05 were considered statistically <bold>significant</bold>.</p></caption><graphic xlink:href="455949_fig1.tif"/></fig>
<table-wrap id="tbl1" position="float" orientation="portrait"><label>Table 1.</label><caption><title>Cytotoxicity of Umbelliprenin isolated from the seeds of <italic>Ferula sinkiangensis</italic> in three cell lines.</title></caption>
<graphic xlink:href="455949_tbl1.tif"/>
</table-wrap>
</sec>
<sec id="s3b"><label>3.2</label><title>The effects of Umbelliprenin on the invasion and migration in AGS and BGC-823 cells</title>
<p>Umbelliprenin was effective in reducing cellular migration in gastric cancer cells. <bold>We performed a wound healing assay, and</bold> images representing <bold>the migration capability of the cells were taken at different time points,</bold> at the same <bold>site and magnification</bold>. <bold>Forty-eight hours after scratching</bold>, <bold>in the presence of Umbelliprenin at its IC<sub>50</sub> value,</bold> the wound was healed approximately <bold>by</bold> 77.4&#x0025; and 64.2&#x0025; for AGS and BGC-823 <bold>cells</bold> compared with <bold>the</bold> control group, respectively <bold>(<xref ref-type="fig" rid="fig2">Figure 2C</xref>)</bold>. The migration assay using the transwell-migration system also showed that Umbelliprenin <bold>effectively inhibited</bold> the migration of AGS and BGC-823 <bold>cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref></bold> and <bold><xref ref-type="fig" rid="fig2">Figure 2B</xref>)</bold>. Furthermore, the inhibitory effect of Umbelliprenin on the invasion of gastric cancer cells was examined <bold>in a transwell assay using</bold> Matrigel-coated filters. Compared with <bold>the</bold> control group, <bold>fewer</bold> AGS and BGC-823 cells <bold>penetrated</bold> the filters after Umbelliprenin treatment<bold>. Additionally,</bold> Umbelliprenin decreased the invasive potential of cells in a dose-dependent manner <bold>(<xref ref-type="fig" rid="fig2">Figure 2A</xref></bold> and <bold><xref ref-type="fig" rid="fig2">Figure 2B</xref>)</bold>. <bold>Therefore, both the</bold> migration and invasion of gastric cancer cells were significantly suppressed after Umbelliprenin treatment.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure"><label>Figure 2:</label><caption><title>Umbelliprenin inhibits the migration and invasion of gastric cancer cell lines.</title><p><bold>A.</bold> The migration or invasion of cells was measured by transwell or matrigel-coated filter transwell assays, <bold>respectively</bold>. Cells were incubated with Umbelliprenin for 24 h, and the migrated or invaded cells were fixed and stained with crystal violet. <bold>B.</bold> The migration and invasion assays data are expressed as the means &#x00B1; SD and represent the mean value of three independent <bold>experiments</bold>. &#x002A;&#x002A;p &#x003C; 0.01, &#x002A;p &#x003C; 0.05. <bold>C.</bold> The migration of AGS and BGC-823 <bold>cells was examined in a</bold> wound healing assay. Cells were scratched and treated with Umbelliprenin. Images were <bold>obtained using</bold> a microscope at 0 h, 24 h, 36 h and 48 h. Data are presented as the <bold>mean</bold> &#x00B1; SD and represent three independent <bold>experiments</bold>. &#x002A;&#x002A;p &#x003C; 0.01, &#x002A;p &#x003C; 0.05 were considered statistically significance.</p></caption><graphic xlink:href="455949_fig2.tif"/></fig>
</sec>
<sec id="s3c"><label>3.3</label><title>Umbelliprenin inhibited the transcriptional activity of &#x03B2;-catenin/TCF in the human gastric cancer cell lines AGS and BGC-823</title>
<p>To explore <bold>whether Umbelliprenin plays a role on the dysregulation of the</bold> Wnt/&#x03B2;-catenin pathway in gastric cancer cells, we examined the <bold>transcriptional</bold> activity of &#x03B2;-catenin/TCF after Umbelliprenin treatment. <bold>For the purpose, we transfected the</bold> TOPFLASH or FOPFLASH <bold>plasmids</bold> into AGS and BGC-823 gastric cancer cells. The transfection efficiency was normalized <bold>with Renilla</bold> luciferase. As shown in <bold><xref ref-type="fig" rid="fig3">Figure 3A</xref></bold> and <bold><xref ref-type="fig" rid="fig3">Figure 3B</xref></bold>, <bold>after 24 h of treatment</bold> Umbelliprenin reduced the <bold>TCF</bold>-dependent luciferase <bold>activity</bold> (TOPflash) in a dose-dependent manner in both gastric cancer cell lines, while it <bold>did not change the activity of the FOPflash control plasmid</bold>. In AGS cells, the <bold>transcriptional activity of TCF was</bold> 62.93&#x0025;, 31.54&#x0025;, and 18.19&#x0025; <bold>relative to</bold> the control group at concentrations of 6, 12 and 24 &#x03BC;M of Umbelliprenin, respectively (P&#x003C;0.05). In BGC-823 cells, the <bold>transcriptional activity of TCF was</bold> 52.91&#x0025;, 43.50&#x0025;, and 21.15&#x0025; <bold>relative to</bold> the control group at concentrations of 12.5, 25 and 50 &#x03BC;M of Umbelliprenin, respectively (P&#x003C;0.05). This indicates that the transcriptional activity of &#x03B2;-catenin/Tcf could be inhibited by Umbelliprenin. <bold>Thus, Umbelliprenin suppresses</bold> the Wnt/&#x03B2;-catenin signaling pathway in the two gastric cancer cell lines.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure"><label>Figure 3:</label><caption><title>Umbelliprenin treatment decreases the activity of the TCF reporter in gastric cancer cells.</title><p><bold>A.</bold> and <bold>B.</bold> AGS and BGC-823 <bold>cells</bold> were transfected with <bold>the</bold> TOPFLASH or FOPFLASH <bold>plasmid</bold> together with <bold>the Renilla plasmid</bold> as control. Cells were then treated with Umbelliprenin (0, 6, 12, 24 &#x03BC;M for AGS <bold>cells</bold> or 0, 12.5, 25, 50 &#x03BC;M for BGC-823 <bold>cells</bold>) for 24 hours. <bold>The luciferase activity was measured and the results were normalized.</bold> The data represent the mean value of three individual experiments. &#x002A;p &#x003C; 0.05 and &#x002A;&#x002A;p &#x003C; 0.01 were considered statistically <bold>significant.</bold></p></caption><graphic xlink:href="455949_fig3.tif"/></fig>
</sec>
<sec id="s3d"><label>3.4</label><title>Inhibition of nuclear translocation of &#x03B2;-catenin by Umbelliprenin</title>
<p>To determine whether Umbelliprenin suppressed &#x03B2;-catenin mediated transcription <bold>by interfering with the nuclear translocation of &#x03B2;-catenin</bold>, we investigated the &#x03B2;-catenin subcellular localization in Umbelliprenin -treated AGS and BGC-823 cells by immunofluorescence staining. As shown in <bold><xref ref-type="fig" rid="fig4">Figure 4A</xref></bold>, &#x03B2;-catenin preferentially accumulated in the nucleus in <bold>the</bold> control group. <bold>By</bold> contrast, after treatment with Umbelliprenin for 24 h, the localization of &#x03B2;-catenin decreased <bold>in the nucleus but increased in</bold> the cytoplasm and at the plasma membrane. This result was confirmed by Western blot analysis in which &#x03B2;-catenin was increased in the cytoplasmic <bold>protein</bold> fraction <bold>and</bold> decreased in the nuclear <bold>protein</bold> fraction <bold>of the</bold> treated groups <bold>(<xref ref-type="fig" rid="fig4">Figure 4B</xref>)</bold>. <bold>The</bold> relative expressions of cytoplasmic and nuclear proteins were shown in <bold><xref ref-type="fig" rid="fig4">Figure 4C</xref></bold>. Therefore, Umbelliprenin may mediate its effect by inhibiting the translocation of &#x03B2;-catenin to the nucleus.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure"><label>Figure 4:</label><caption><title>Umbelliprenin inhibits the nuclear translocation of &#x03B2;-catenin in gastric cancer cells.</title><p><bold>A.</bold> The translocation of &#x03B2;-catenin was examined by immunostaining. Cells were treated with UM (0, 6, 12, 24 &#x03BC;M for AGS <bold>cells</bold> or 0, 12.5, 25, 50 &#x03BC;M for BGC-823 <bold>cells</bold>) for 24 h, stained with <bold>the</bold> anti-&#x03B2;-catenin antibody and <bold>analysed</bold> using <bold>the</bold> Image Xpress Micro imaging system (MD, USA). <bold>B.</bold> Protein expressions were detected by western blot. After treatment with Umbelliprenin (0, 6, 12, 24 &#x03BC;M for AGS <bold>cells</bold> or 0,12.5, 25, 50 &#x03BC;M for BGC-823 <bold>cells</bold>) for 24 h. Cellular fractionation was carried out to determine the cellular localization of &#x03B2;-catenin. Lamin B and &#x03B2;-actin were used as <bold>controls for</bold> nuclear fraction and cytoplasmic fraction, <bold>respectively</bold>. <bold>C. The</bold> relative expression of cytoplasmic and nuclear proteins was analyzed. <bold>The</bold> results obtained from a <bold>representative</bold> experiment are shown (n=3). Statistical significance was &#x002A;&#x002A;p &#x003C; 0.01.</p></caption><graphic xlink:href="455949_fig4.tif"/></fig>
</sec>
<sec id="s3e"><label>3.5</label><title>Umbelliprenin inhibits Wnt signaling by decreasing the phosphorylation of GSK-3&#x03B2; and reducing the downstream effectors of Wnt signaling</title>
<p>Wnt signaling substantially impacts gastric tumorigenesis and prognosis [<xref ref-type="bibr" rid="c5">Bohle et al., 2010</xref>]. <bold>To</bold> further determine the mechanisms by which Umbelliprenin inhibits cellular proliferation, migration and invasion, we studied the Wnt signaling. The expression levels of Wnt signaling-associated proteins in both AGS and BGC-823 cells were measured by western blot. Wnt-2, &#x03B2;-catenin, and GSK-3&#x03B2;, potential modulators of Wnt signaling, as well as the downstream targets of Wnt signaling Survivin and c-myc, were significantly reduced <bold>in Umbelliprenin treated cells</bold> compared to the control group (<bold><xref ref-type="fig" rid="fig5">Figure 5A</xref></bold> and <bold><xref ref-type="fig" rid="fig5">Figure 5C</xref>)</bold>. <bold>The</bold> relative expressions were shown in <bold><xref ref-type="fig" rid="fig5">Figure 5B</xref></bold> and <bold><xref ref-type="fig" rid="fig5">Figure 5D</xref></bold>.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure"><label>Figure 5:</label><caption><title>Umbelliprenin downregulates the Wnt signal pathway, and Survivin and c-myc protein expression levels.</title><p><bold>The expression of the regulatory proteins of the</bold> Wnt signal pathway, Survivin and c-myc protein were determined by western blot. <bold>A.</bold> and <bold>C.</bold> AGS or BGC-823 cells were treated with Umbelliprenin (0, 6, 12, 24 &#x03BC;M for AGS <bold>cells</bold> or 0, 12.5, 25, 50 &#x03BC;M for BGC-823 <bold>cells</bold>) for 24 h. &#x03B2;-actin was used to confirm equal protein loading. <bold>B.</bold> and <bold>D. The</bold> relative expression levels of proteins are <bold>shown.</bold> All tests were <bold>performed</bold> in triplicate. &#x002A;p &#x003C; 0.05 and &#x002A;&#x002A; p&#x003C;0.01 were considered statistically significant.</p></caption><graphic xlink:href="455949_fig5.tif"/></fig>
</sec>
<sec id="s3f"><label>3.6</label><title>The safety of Umbelliprenin in BGC-823 tumor xenograft models</title>
<p>Previous <bold>studies</bold> showed that Umbelliprenin could effectively inhibit the growth of tumor <italic>in vivo</italic>. Thus, we evaluated the safety of Umbelliprenin in BGC-823 tumor xenograft models. All mice tolerated the treatment procedure well <bold>and did not show</bold> toxic symptoms or signs. <bold>The analysis of biochemical markers for the liver, as ALT and AST, showed no significant change between the</bold> different groups <bold>(<xref ref-type="table" rid="tbl2">Table 2</xref>)</bold>. In addition, no histological abnormality was shown in <bold>the</bold> lungs, liver, heart, and kidneys of mice between <bold>the</bold> Umbelliprenin treatment groups and control group at the end of <bold>the</bold> treatment (<bold><xref ref-type="fig" rid="fig6">Figure 6</xref></bold>). Together, these data suggest that Umbelliprenin effectively inhibits tumor growth, <bold>and does not cause</bold> obvious drug-induced adverse effects.</p>
<table-wrap id="tbl2" position="float" orientation="portrait"><label>Table 2.</label><caption><title>Serum analysis for liver function (mean &#x00B1; SD, n = 8)</title>
<p>Blood samples were collected and centrifuged at 12,000 rpm for 15 min to obtain the serum. Liver function was evaluated based on the serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). All biochemical parameters were evaluated by an automated biochemical analyzer (Beckman).</p>
</caption>
<graphic xlink:href="455949_tbl2.tif"/>
</table-wrap>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure"><label>Figure 6:</label><caption><title>Low toxicity of Umbelliprenin <italic>in vivo</italic>.</title><p>The results showed representative <bold>hematoxylin-eosin</bold> staining <bold>to investigate the</bold> potential toxicity of Umbelliprenin in lung, heart, kidney and liver of Umbelliprenin -treated and control mice on day 12 <bold>(n = 8).</bold></p></caption><graphic xlink:href="455949_fig6.tif"/></fig>
</sec>
</sec>
<sec id="s4"><label>4.</label><title>Discussion</title>
<p>Natural products with potential for gastric cancer treatment have <bold>received much</bold> attention. Umbelliprenin has been reported to possess <bold>the</bold> promising effect of inducing apoptosis <bold>in</bold> a variety of cancer cell types such as leukemia, breast cancer and bladder carcinoma [<xref ref-type="bibr" rid="c14">Mousavi et al., 2015</xref>; <xref ref-type="bibr" rid="c16">Gholami et al., 2013</xref>; <xref ref-type="bibr" rid="c17">Haghighi et al., 2014</xref>] and <bold>exhibits</bold> biological effects in multiple signal transduction pathways. For example, <bold>a</bold> study showed that Umbelliprenin could activate both <bold>the</bold> intrinsic and extrinsic pathways of apoptosis in <bold>the</bold> Jurkat T-CLL cell line, which accounted for the inhibition of cellular proliferation and apoptosis induction [<xref ref-type="bibr" rid="c16">Gholami et al., 2013</xref>]. <bold>Therefore,</bold> further studies on the <bold>anti-gastric cancer effects of Umbelliprenin</bold> are necessary. Our previous results showed that Umbelliprenin <bold>among seven compounds isolated from the seeds of <italic>F. sinkiangensis</italic>, exhibits the strongest antitumor effect <italic>in vivo</italic> and <italic>in vitro</italic>.</bold> Based on these results, we performed further research on Umbelliprenin. In the present study, we demonstrated the <bold>anti-metastatic and anti-proliferative</bold> effects of Umbelliprenin on <bold>the</bold> AGS and BGC-823 gastric cancer cell lines <italic>in vitro</italic> and its safety <italic>in vivo</italic>. These results indicated that Umbelliprenin might be an effective inhibitor of tumor <bold>migration</bold>, <bold>and were obtained using</bold> wound healing, transwell migration and invasion assays. We also demonstrated that the <bold>mechanism</bold> of action of Umbelliprenin include the inhibition of <bold>the</bold> Wnt signaling pathways <bold>and</bold> the decrease of c-myc and Survivin.</p>
<p>The activation of <bold>the</bold> Wnt/&#x03B2;-catenin signaling is found <bold>approximately</bold> 30&#x0025; to 50&#x0025; of gastric cancer tissues and in many gastric cancer cell lines [<xref ref-type="bibr" rid="c18">Ooi et al., 2009</xref>]. &#x03B2;-catenin is a multifunctional protein that was found as <bold>an</bold> E-cadherin-binding protein involved in the regulation of <bold>cell-to-cell</bold> adhesion and works as a transcriptional regulator in the Wnt signaling pathway [<xref ref-type="bibr" rid="c19">Kikuchi et al., 2011</xref>]. It accumulates in the cytoplasm and translocates to the nucleus, <bold>where it</bold> behaves as transcriptional coregulatory <bold>factor</bold> by interacting with <bold>the</bold> TCF/LEF complex and activates target oncogenes, <bold>such as</bold> c-myc and Survivin [<xref ref-type="bibr" rid="c20">Eastman et al., 1999</xref>; <xref ref-type="bibr" rid="c21">Zhang et al., 2014</xref>]. Our results suggest that Umbelliprenin down-regulates Wnt, resulting in <bold>the</bold> decrease <bold>of</bold> phosphorylated GSK-3&#x03B2; and reduction of Wnt downstream effectors, <bold>such as</bold> &#x03B2;-catenin, Survivin, c-myc, MMP2 and MMP9. Furthermore, Umbelliprenin treatment caused the inhibition of <bold>the</bold> nuclear translocation of &#x03B2;-catenin and the reduction of <bold>the activity of the TCF-reporter</bold>. Although results suggest that Umbelliprenin <bold>interferes with the</bold> Wnt/beta-catenin signaling and <bold>therefore inhibits the activity of the TCF reporter, reduction of the</bold> reporter activity might be partially caused <bold>the Umbelliprenin-induced</bold> migration and invasion. Our results are consistent with <bold>those</bold> previous studies showing that decreased Wnt expression is associated with decreased phosphorylation of GSK-3&#x03B2;; decreased <bold>expression of</bold> &#x03B2;-catenin, c-myc and Survivin; <bold>lower activity of the TCF reporter; and reduced</bold> migration and invasion [<xref ref-type="bibr" rid="c22">Luo et al., 1999</xref>].</p>
<p>Taken together, <bold>for the first time,</bold> we showed strong evidence that Umbelliprenin isolated from the <bold>seeds</bold> of <italic>F. sinkiangensis</italic> can inhibit <bold>cell</bold> growth, migration and invasion, at least in part, through the Wnt signaling pathway. Other reports have shown that the Wnt antagonists inhibit the growth of HCC cells <italic>in vitro</italic> and <italic>in vivo</italic> <bold>through inhibition of the formation of the</bold> TCF-4/&#x03B2;-catenin complex and its transcriptional activity <bold>and</bold> downregulation of <bold>the</bold> &#x03B2;-catenin/TCF-4 target genes c-myc and Survivin [<xref ref-type="bibr" rid="c23">Wei et al., 2010</xref>]. <bold>By</bold> contrast, we found that Umbelliprenin inhibits the Wnt pathway by decreasing nuclear translocation of &#x03B2;-catenin rather than <bold>disrupting the</bold> TCF-4/&#x03B2;-catenin complex. Therefore, <bold>treatments that</bold> combine Umbelliprenin with <bold>an</bold> antagonist of TCF-4/&#x03B2;-catenin may lead to promising effects on suppressing the activation of <bold>the</bold> Wnt signaling pathway.</p>
<p>In conclusion, our data indicate that Umbelliprenin <bold>has anti-migration</bold> effects in AGS and BGC-823 gastric cancer cells, <bold>targets</bold> the Wnt signaling pathway, and <bold>exhibits</bold> good safety during the treatment in <bold>the</bold> BGC-823 xenograft <italic>in vivo</italic> <bold>model</bold>: <bold>indeed,</bold> no <bold>abnormalities in regard to</bold> body weight, daily diet, liver function and histological characteristics <bold>of</bold> lung, spleen, heart, kidney and liver tissue were observed. Therefore, Umbelliprenin could be a promising approach for gastric cancer treatment; however, further investigations are necessary.</p>
<sec id="s4a"><title>Conflict of interest</title>
<p>The authors declare that they have no competing interests</p>
</sec>
</sec>
</body>
<back>
<ack><title>Acknowledgments</title>
<p>We would like to thank Addgene for providing us <bold>with the</bold> M50 Super 8x TOPFlash (12457), M51 Super 8x FOPFlash (TOPFlash mutant) (12457) and pRL-SV40P (27163) <bold>plasmids</bold>. This work <bold>was supported</bold> by the National Natural Science Foundation of China (No. 81460661 and No. 81460586), the Ministry of Science and Technology of the People's Republic of China, and <bold>the</bold> Major Scientific and Technological Special Project for &#x201C;Significant New Drugs Formulation&#x201D; (Grant No. 2012ZX09501001-004 and 2012ZX09301-002-001-026). This work was also supported by <bold>the</bold> Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname>, <given-names>J.H.</given-names></string-name>, <string-name><surname>Chin</surname>, <given-names>H.M.</given-names></string-name>, <string-name><surname>Jun</surname>, <given-names>K.H.</given-names></string-name>, <year>2015</year>. <article-title>Surgical outcomes and survival after gastrectomy in octogenarians with gastric cancer</article-title>. <source>J. Surg. Res</source>. <volume>198</volume>, <fpage>80</fpage>-<lpage>86</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Zeng</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>S.</given-names></string-name>, <year>2016</year>. <article-title>Chen T and Chen W. National estimates of cancer prevalence in China, 2011</article-title>. <source>Cancer Lett</source>. <volume>370</volume>:<fpage>33</fpage>-<lpage>38</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Zeng</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Guo</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Zou</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Tang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Huang</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Song</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Shen</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Gu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Jin</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Ge</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Zhu</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Dong</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Guo</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Du</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>He</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Coleman</surname>, <given-names>M.P.</given-names></string-name>, <string-name><surname>Baade</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>X.Q.</given-names></string-name>, <year>2015</year>. <article-title>Cancer survival in China, 2003-2005: a population-based study</article-title>. <source>Int. J. Cancer</source>. <volume>136</volume>:<fpage>1921</fpage>-<lpage>1930</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Climent</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Hidalgo</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Vidal</surname>, <given-names>&#x00D3;.</given-names></string-name>, <string-name><surname>Puig</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Iglesias</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Cuatrecasas</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ram&#x00F3;n</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Garc&#x00ED;a-Alb&#x00E9;niz</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Grande</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Pera</surname>, <given-names>M.</given-names></string-name>, <year>2015</year>. <article-title>Postoperative complications do not impact on recurrence and survival after curative resection of gastric cancer</article-title>. <source>Eur. J. Surg. Oncol</source>. <volume>42</volume>:<fpage>132</fpage>-<lpage>139</lpage></mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Bohle</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Pera</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Pascual</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Alonso</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Mayol</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Salvado</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Schmidt</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Grande</surname>, <given-names>L.</given-names></string-name>, <year>2010</year>. <article-title>Postoperative intra-abdominal infection increases angiogenesis and tumor recurrence after surgical excision of colon cancer in mice</article-title>. <source>Surgery</source>. <volume>147</volume>:<fpage>120</fpage>-<lpage>126</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Cho</surname>, <given-names>E.J.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>H.K.</given-names></string-name>, <string-name><surname>Jeong</surname>, <given-names>T.D.</given-names></string-name>, <string-name><surname>Ko</surname>, <given-names>D.H.</given-names></string-name>, <string-name><surname>Bae</surname>, <given-names>S.E.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Choe</surname>, <given-names>J.W.</given-names></string-name>, <string-name><surname>Chun</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Jung</surname>, <given-names>H.Y.</given-names></string-name>, <string-name><surname>Min</surname>, <given-names>W.K.</given-names></string-name>, <year>2016</year>. <article-title>Method evaluation of pepsinogen I/II assay based on chemiluminescent immunoassays and comparison with other test methods</article-title>. <source>Clinica Chimica Acta</source>. <volume>452</volume>:<fpage>149</fpage>-<lpage>154</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Roviello</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Polom</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Petrioli</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Marano</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Marrelli</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Paganini</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Savelli</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Generali</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Franco</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ravelli</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Roviello</surname>, <given-names>F.</given-names></string-name>, <year>2016</year>. <article-title>Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives</article-title>. <source>Tumour Biol</source>. <volume>37</volume>:<fpage>1</fpage>-<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Tang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Yue</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yao</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ma</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Tian</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Ge</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Han</surname>, <given-names>X.</given-names></string-name>, <year>2014</year>. <article-title>Inhibition of invasion and metastasis by DMBT, a novel trehalose derivative, through Akt/GSK-3&#x03B2;/&#x03B2;-catenin pathway in B16BL6 cells</article-title>. <source>Chem-Bioll Interact</source>. <volume>222</volume>:<fpage>7</fpage>-<lpage>17</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Chiurillo</surname>, <given-names>M.A.</given-names></string-name>, <year>2015</year>. <article-title>Role of the Wnt/&#x03B2;-catenin pathway in gastric cancer: An in-depth literature review</article-title>. <source>World J. Exp. Med</source>. <volume>5</volume>:<fpage>84</fpage>-<lpage>102</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Guttridge</surname>, <given-names>D.C.</given-names></string-name>, <string-name><surname>You</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Fribley</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mayo</surname>, <given-names>M.W.</given-names></string-name>, <string-name><surname>Kitajewski</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>C.Y.</given-names></string-name>, <year>2001</year>. <article-title>Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription</article-title>. <source>J. Cell Biol</source>. <volume>152</volume>:<fpage>87</fpage>-<lpage>96</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Dong</surname>, <given-names>G.Z.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>S.Y.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>H.Y.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Jeong</surname>, <given-names>J.H.</given-names></string-name>, <string-name><surname>Jeon</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>H.J.</given-names></string-name>, <string-name><surname>Ryu</surname>, <given-names>J.H.</given-names></string-name>, <year>2015</year>. <article-title>Diarylheptanoids from lesser galangal suppress human colon cancer cell growth through modulating Wnt/&#x03B2;-catenin pathway</article-title>. <source>J. Funct. Foods</source>. <volume>18</volume>:<fpage>47</fpage>-<lpage>57</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhu</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <year>2013</year>. <article-title>Chinese herbal medicines for induction of remission in advanced or late gastric cancer</article-title>. <source>The Cochrane database of systematic reviews</source>. DOI: <pub-id pub-id-type="doi">10.1002/14651858.CD005096.pub4</pub-id>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Ziai</surname>, <given-names>S.A.</given-names></string-name>, <string-name><surname>Gholami</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Iranshahi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zamani</surname>, <given-names>A.H.</given-names></string-name>, <string-name><surname>Jeddi-Tehrani</surname>, <given-names>M.</given-names></string-name>, <year>2012</year>. <article-title>Umbelliprenin Induces Apoptosis in CLL Cell Lines</article-title>. <source>Iran J. Pharm. Res</source>. <volume>11</volume>:<fpage>653</fpage>-<lpage>659</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Mousavi</surname>, <given-names>S.H.</given-names></string-name>, <string-name><surname>Davari</surname>, <given-names>A.S.</given-names></string-name>, <string-name><surname>Iranshahi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sabouri-Rad</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Tayarani</surname>, <given-names>N.Z.</given-names></string-name>, <year>2015</year>. <article-title>Comparative analysis of the cytotoxic effect of 7-prenyloxycoumarin compounds and herniarin on MCF-7 cell line</article-title>. <source>Avicenna J. Phytomed</source>. <volume>5</volume>:<fpage>520</fpage>-<lpage>530</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Si</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Huo</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Cao</surname>, <given-names>L.</given-names></string-name>, <year>2015</year>. <article-title>Umbelliprenin and lariciresinol isolated from a long-term-used herb medicine Ferula sinkiangensis induce apoptosis and G0/G1 arresting in gastric cancer cells</article-title>. <source>RSC Adv</source>. <volume>5</volume>:<fpage>91006</fpage>-<lpage>91017</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Gholami</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Jeddi-Tehrani</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Iranshahi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zarnani</surname>, <given-names>A.H.</given-names></string-name>, <string-name><surname>Ziai</surname>, <given-names>S.A.</given-names></string-name>, <year>2013</year>. <article-title>Umbelliprenin from Ferula szowitsiana Activates both Intrinsic and Extrinsic Pathways of Apoptosis in Jurkat T-CLL cell line</article-title>. <source>Iran J. Pharm. Res</source>. <volume>12</volume>:<fpage>371</fpage>-<lpage>376</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Haghighi</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Matin</surname>, <given-names>M.M.</given-names></string-name>, <string-name><surname>Bahrami</surname>, <given-names>A.R.</given-names></string-name>, <string-name><surname>Iranshahi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Rassouli</surname>, <given-names>F.B.</given-names></string-name>, <string-name><surname>Haghighitalab</surname>, <given-names>A.</given-names></string-name>, <year>2014</year>. <article-title>The cytotoxic activities of 7-isopentenyloxycoumarin on 5637 cells via induction of apoptosis and cell cycle arrest in G2/M stage</article-title>. <source>DARU</source>. <volume>22</volume>:<fpage>3</fpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Ooi</surname>, <given-names>C.H.</given-names></string-name>, <string-name><surname>Ivanova</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tan</surname>, <given-names>I.B.</given-names></string-name>, <string-name><surname>Tao</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Ward</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Koo</surname>, <given-names>J.H.</given-names></string-name>, <string-name><surname>Gopalakrishnan</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Zhu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>L.L.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Rha</surname>, <given-names>S.Y.</given-names></string-name>, <string-name><surname>Chung</surname>, <given-names>H.C.</given-names></string-name>, <string-name><surname>Ganesan</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>So</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Soo</surname>, <given-names>K.C.</given-names></string-name>, <string-name><surname>Lim</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Chan</surname>, <given-names>W.H.</given-names></string-name>, <string-name><surname>Wong</surname>, <given-names>W.K.</given-names></string-name>, <string-name><surname>Bowtell</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Yeoh</surname>, <given-names>K.G.</given-names></string-name>, <string-name><surname>Grabsch</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Boussioutas</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tan</surname>, <given-names>P.</given-names></string-name>, <year>2009</year>. <article-title>Oncogenic pathway combinations predict clinical prognosis in gastric cancer</article-title>. <source>Plos Gen</source>. <volume>5</volume>:<fpage>e1000676</fpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Kikuchi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Sato</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Matsumoto</surname>, <given-names>S.</given-names></string-name>, <year>2011</year>. <article-title>New insights into the mechanism of Wnt signaling pathway activation</article-title>. <source>Int. Rev. Cell Mol. Biol</source>. <volume>291</volume>:<fpage>21</fpage>-<lpage>71</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Eastman</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Grosschedl</surname>, <given-names>R.</given-names></string-name>, <year>1999</year>. <article-title>Regulation of LEF-1/TCF transcription factors by Wnt and other signals</article-title>. <source>Curr. Opin. Cell Biol</source>. <volume>11</volume>:<fpage>233</fpage>-<lpage>240</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kong</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Zhan</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Ye</surname>, <given-names>Z.N.</given-names></string-name>, <string-name><surname>Pu</surname>, <given-names>J.X.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>H.D.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <year>2014</year>. <article-title>Two Natural ent-kauranoids as Novel Wnt Signaling Inhibitors</article-title>. <source>Nat. Prod. Bioprospect</source>. <volume>4</volume>:<fpage>135</fpage>-<lpage>140</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Luo</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lubaroff</surname>, <given-names>D.M.</given-names></string-name>, <string-name><surname>Hendrix</surname>, <given-names>M.J.</given-names></string-name>, <year>1999</year>. <article-title>Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection</article-title>. <source>Cancer Res</source>. <volume>59</volume>:<fpage>3552</fpage>-<lpage>3556</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Wei</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Chua</surname>, <given-names>M.S.</given-names></string-name>, <string-name><surname>Grepper</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>So</surname>, <given-names>S.</given-names></string-name>, <year>2010</year>. <article-title>Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo</article-title>. <source>Int. J. Cancer</source>. <volume>126</volume>:<fpage>2426</fpage>-<lpage>2436</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>